Community-acquired bacteraemia by Klebsiella pneumoniae producing KPC-3 and resistant to ceftazidime/avibactam.

Azabicyclo Compounds Bacteremia Ceftazidime / pharmacology Drug Combinations Humans Klebsiella Infections / microbiology Klebsiella pneumoniae / genetics Microbial Sensitivity Tests Trimethoprim, Sulfamethoxazole Drug Combination
Bacteraemia Ceftazidime/avibactam-resistance Community-acquired Klebsiella pneumoniae

Journal

Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459

Informations de publication

Date de publication:
09 2022
Historique:
received: 08 05 2022
revised: 04 07 2022
accepted: 16 07 2022
pubmed: 26 7 2022
medline: 14 9 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

To describe the clinical and microbiological features of a case of community-acquired infection by KPC-producing K. pneumoniae (KPCKP) resistant to ceftazidime/avibactam (CAZ-AVI). Identification of microorganisms was performed with MALDI Biotyper CA System (BrukerDaltonics, Madrid, Spain). Antimicrobial susceptibility testing was performed using Sensitre EURGNCOL panels (Thermo Fisher Scientific, Madrid, Spain) and gradient strips (Etest, bioMérieux, Madrid, Spain) in the case of CAZ-AVI, using EUCAST breakpoints for interpretation. Whole genome sequencing of blood culture and rectal swab isolates was performed using the Illumina NovaSeq 6000 sequencing system, with 2 × 150-bp paired-end reads (Illumina, Inc.). Blood culture and rectal swab KPCKP isolates were resistant to carbapenems and to CAZ-AVI. The blood culture isolate showed susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX), but the rectal swab culture isolate was resistant to this antibiotic. Both isolates belonged to clonal lineage ST512, harboured a single copy of bla Resistance to ceftazidime-avibactam is an emerging nosocomial problem. This case shows that CAZ-AVI-resistant KPCKP strains may disseminate into the community and cause serious infections.

Identifiants

DOI: 10.1016/j.jgar.2022.07.017 PMID: 35878781
pubmed: 35878781
pii: S2213-7165(22)00185-0
doi: 10.1016/j.jgar.2022.07.017
pii:
doi:

Substances chimiques

Azabicyclo Compounds 0
Drug Combinations 0
avibactam, ceftazidime drug combination 0
avibactam 7352665165
Trimethoprim, Sulfamethoxazole Drug Combination 8064-90-2
Ceftazidime 9M416Z9QNR

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-402

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest JTC has been a consultant and has received research/educational funds from Pfizer, Merck, Shionogi, and Menarini. LMM has been a consultant for MSD and Shionogi, has served as a speaker for Merck, Pfizer, AbbVie, and AstraZeneca, and has received research support from Janssen-Cilag and Pfizer. All other authors declare no conflicts of interest.

Auteurs

Isabel Machuca (I)

Unit of Infectious Diseases, Reina Sofía University Hospital, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain.

Julia Guzmán-Puche (J)

Unit of Microbiology, Reina Sofía University Hospital, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain.

E Pérez-Nadales (E)

Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain.

I Gracia-Ahufinger (I)

Unit of Microbiology, Reina Sofía University Hospital, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain.

A Mendez (A)

Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain.

A Cano (A)

Unit of Infectious Diseases, Reina Sofía University Hospital, Cordoba, Spain.

J J Castón (JJ)

Unit of Infectious Diseases, Reina Sofía University Hospital, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain.

A Domínguez (A)

Department of Anesthesiology, Resuscitation and Therapeutics of Pain, Reina Sofía University Hospital, Cordoba, Spain.

J Torre-Cisneros (J)

Unit of Infectious Diseases, Reina Sofía University Hospital, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain; Department of Medical and Surgical Sciences, University of Cordoba, Cordoba, Spain. Electronic address: julian.torre.sspa@juntadeandalucia.es.

L Martínez-Martínez (L)

Unit of Microbiology, Reina Sofía University Hospital, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), Cordoba, Spain; Department of Agricultural Chemistry, Soil Science and Microbiology, University of Cordoba, Cordoba, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques, cycle ponté › Composés hétérocycliques bicycliques › Composés azabicycliques › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Bactériémie › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Céfaloridine › Ceftazidime › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram négatif › Infections à Enterobacteriaceae › Infections à Klebsiella › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Klebsiella › Klebsiella pneumoniae › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Community-acquired bacteraemia by Klebsiella...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Association triméthoprime-sulfaméthoxazole › Community-acquired bacteraemia by Klebsiella...